<< Elsevier journal Vaccine releases a supplement dedicated to vaccines for biodefense | Companies, individuals and academic organizations recognized with GCOI awards >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Norsk | Русский | Svenska | Polski

US and European market for radiopharmaceuticals continues to gain momentum

Published on November 20, 2009 at 2:41 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/410c60/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - A US and European Market Analysis" report to their offering.

The market for radiopharmaceuticals continues to gain momentum with heightened interest in therapeutic efficiency, acceptance and utilization of nuclear medicine equipment, as well as development of newer diagnostic and therapeutic agents. Besides oncology applications, the nuclear medicine field is presently exploring the possibility of extending the scope and functionality of radiopharmaceuticals to other disease applications such as infection imaging, nephrology and neurology applications. Advancements in nuclear medicine technology would represent a key strategic factor in opening up new clinical opportunities for radiopharmaceutical agents.

These and other market data and trends are presented in "Radiopharmaceuticals: A US and European Market Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

http://www.researchandmarkets.com/research/410c60/radiopharmaceutica

695b9412-1af5-4d8a-a9fc-d0801585eab5|0|.0

Posted in: Pharmaceutical News

Tags: Antibody, Brain, Brain Cancer, Cancer, Cell, Ciprofloxacin, Follicular Lymphoma, Lung Cancer, Lymphoma, Nephrology, Neurology, Nuclear Medicine, Oncology, Radiation Therapy, Radiotherapy, Zevalin

Related posts

Cholesterol receptor allows entry of HCV virus into human liver cellsA molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also al...
Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher diseaseGenzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 ...
Alnylam presents ALN-VSP Phase I trial results for liver cancerAlnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from...
Brain fever mistaken as migraine kills a 30 year old womanJane Harrop, a 30 year old British woman was complaining of headaches for several days that made her...
Transplant centers should utilize DCD kidneys to minimize patients’ mortality ratesIn the United States over 80,000 people are on the kidney transplant waiting list, and thousands die...
Report on major players and opportunities in the antiviral marketResearch and Markets has announced the addition of Decision Resources, Inc.'s new report "Dealmaking...
Second-quarter fiscal 2010 results announced by PharmacyclicsPharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31...
Market Media Connect retained as Northwest Biotherapeutics' communications agency of recordNorthwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized c...
TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trialTetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort...
US and European radiopharmaceuticals market reportReportlinker.com announces that a new market research report is available in its catalogue: US and E...
Giant Eagle offers generic prescription antibiotics for free at its in-store pharmaciesAt a time when many families affected by a difficult economy are struggling with the costs of prescr...
New immune therapy for kidney cancer testedResearchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate wh...
Risk assessment tool finds that blacks with breathing conditions have higher risk for developing lung cancer than whitesBlacks with chronic obstructive pulmonary disease -- including chronic bronchitis and some types of ...
High dose rate brachytherapy treatment for prostate cancerUp to 79% preservation of potency and less than 2% incontinence are the striking results of a clinic...
Molecular imaging provides a better way to visualize heart diseaseTechnically advanced molecular imaging provides a 3-D way to significantly improve the diagnosis of ...
Suppression of growth hormone and related compounds beginning in early adulthood may delay the onset or progression of several types of cancerA modest suppression of growth hormone and related compounds beginning in early adulthood may delay ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.